- Home
- CLDX vs GOF Comparison
CLDX vs GOF Comparison
Compare CLDX & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLDX | GOF |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 1995 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CLDX | GOF |
|---|---|---|
| Price | $42.66 | $10.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $46.60 | N/A |
| AVG Volume (30 Days) | 963.5K | ★ 1.1M |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,743,000.00 | N/A |
| Revenue This Year | $111.39 | N/A |
| Revenue Next Year | $235.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 87.78 | N/A |
| 52 Week Low | $20.37 | $10.36 |
| 52 Week High | $45.14 | $15.16 |
Technical Indicators
Market Signals| Indicator | CLDX | GOF |
|---|---|---|
| Relative Strength Index (RSI) | 63.24 | 35.26 |
| Support Level | $28.51 | $10.36 |
| Resistance Level | N/A | $11.02 |
| Average True Range (ATR) | 1.71 | 0.10 |
| MACD | 0.24 | 0.01 |
| Stochastic Oscillator | 72.23 | 5.26 |
Price Performance
Historical ComparisonAbout CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.